Global Peanut Allergy Therapeutics Market Size, Share, Trends and Forecast 2022-2030

Description

Peanuts are one of the food allergens most commonly associated with anaphylaxis, a sudden and potentially deadly condition that requires immediate attention and treatment.
Industry Insights

The global Peanut Allergy Therapeutics market size is projected to reach US$ 6416.9 million by 2028, from US$ 678.4 million in 2021, at a CAGR of 37.4% during 2022-2028.

United States is the largest consumption place, with a consumption market share nearly 45% in 2019. Following United States, Europe is the second largest consumption place with the consumption market share of 31%.

Market competition is intense. Mylan, Bayer, UCB Pharma, J & J, Perrigo,top 5 players took 52% market share.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Peanut Allergy Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Peanut Allergy Therapeutics market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Peanut Allergy Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Peanut Allergy Therapeutics market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Peanut Allergy Therapeutics market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Peanut Allergy Therapeutics Breakdown Data by Type

Epinephrine Injection

Antihistamines

Oral Immunotherapy

Other

Peanut Allergy Therapeutics Breakdown Data by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Other

Regional Analysis

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Mylan

Bayer

UCB Pharma

J & J

Perrigo

GSK

Kaleo

Amneal Pharma

ALK Abello

Aimmune Therapeutics

HUAPONT Pharm

Allergy Therapeutics

ASIT Biotech

Sanofi

DBV Technologies

HAL Allergy

Intrommune Therapeutics

TABLE OF CONTENT

1 Report Overview
1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Peanut Allergy Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Epinephrine Injection

1.2.3 Antihistamines

1.2.4 Oral Immunotherapy

1.2.5 Other

1.3 Market by Distribution Channel

1.3.1 Global Peanut Allergy Therapeutics Market Share by Distribution Channel: 2017 VS 2021 VS 2028

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Peanut Allergy Therapeutics Market Perspective (2017-2028)

2.2 Peanut Allergy Therapeutics Growth Trends by Region

2.2.1 Peanut Allergy Therapeutics Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Peanut Allergy Therapeutics Historic Market Size by Region (2017-2022)

2.2.3 Peanut Allergy Therapeutics Forecasted Market Size by Region (2023-2028)

2.3 Peanut Allergy Therapeutics Market Dynamics

2.3.1 Peanut Allergy Therapeutics Industry Trends

2.3.2 Peanut Allergy Therapeutics Market Drivers

2.3.3 Peanut Allergy Therapeutics Market Challenges

2.3.4 Peanut Allergy Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peanut Allergy Therapeutics Players by Revenue

3.1.1 Global Top Peanut Allergy Therapeutics Players by Revenue (2017-2022)

3.1.2 Global Peanut Allergy Therapeutics Revenue Market Share by Players (2017-2022)

3.2 Global Peanut Allergy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Peanut Allergy Therapeutics Revenue

3.4 Global Peanut Allergy Therapeutics Market Concentration Ratio

3.4.1 Global Peanut Allergy Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peanut Allergy Therapeutics Revenue in 2021

3.5 Peanut Allergy Therapeutics Key Players Head office and Area Served

3.6 Key Players Peanut Allergy Therapeutics Product Solution and Service

3.7 Date of Enter into Peanut Allergy Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Peanut Allergy Therapeutics Breakdown Data by Type

4.1 Global Peanut Allergy Therapeutics Historic Market Size by Type (2017-2022)

4.2 Global Peanut Allergy Therapeutics Forecasted Market Size by Type (2023-2028)

5 Peanut Allergy Therapeutics Breakdown Data by Distribution Channel

5.1 Global Peanut Allergy Therapeutics Historic Market Size by Distribution Channel (2017-2022)

5.2 Global Peanut Allergy Therapeutics Forecasted Market Size by Distribution Channel (2023-2028)

6 North America

6.1 North America Peanut Allergy Therapeutics Market Size (2017-2028)

6.2 North America Peanut Allergy Therapeutics Market Size by Country (2017-2022)

6.3 North America Peanut Allergy Therapeutics Market Size by Country (2023-2028)

6.4 United States

6.5 Canada

7 Europe

7.1 Europe Peanut Allergy Therapeutics Market Size (2017-2028)

7.2 Europe Peanut Allergy Therapeutics Market Size by Country (2017-2022)

7.3 Europe Peanut Allergy Therapeutics Market Size by Country (2023-2028)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Peanut Allergy Therapeutics Market Size (2017-2028)

8.2 Asia-Pacific Peanut Allergy Therapeutics Market Size by Country (2017-2022)

8.3 Asia-Pacific Peanut Allergy Therapeutics Market Size by Country (2023-2028)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

9 Latin America

9.1 Latin America Peanut Allergy Therapeutics Market Size (2017-2028)

9.2 Latin America Peanut Allergy Therapeutics Market Size by Country (2017-2022)

9.3 Latin America Peanut Allergy Therapeutics Market Size by Country (2023-2028)

9.4 Mexico

9.5 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peanut Allergy Therapeutics Market Size (2017-2028)

10.2 Middle East & Africa Peanut Allergy Therapeutics Market Size by Country (2017-2022)

10.3 Middle East & Africa Peanut Allergy Therapeutics Market Size by Country (2023-2028)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

11 Key Players Profiles

11.1 Mylan

11.1.1 Mylan Company Detail

11.1.2 Mylan Business Overview

11.1.3 Mylan Peanut Allergy Therapeutics Introduction

11.1.4 Mylan Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.1.5 Mylan Recent Development

11.2 Bayer

11.2.1 Bayer Company Detail

11.2.2 Bayer Business Overview

11.2.3 Bayer Peanut Allergy Therapeutics Introduction

11.2.4 Bayer Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.2.5 Bayer Recent Development

11.3 UCB Pharma

11.3.1 UCB Pharma Company Detail

11.3.2 UCB Pharma Business Overview

11.3.3 UCB Pharma Peanut Allergy Therapeutics Introduction

11.3.4 UCB Pharma Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.3.5 UCB Pharma Recent Development

11.4 J & J

11.4.1 J & J Company Detail

11.4.2 J & J Business Overview

11.4.3 J & J Peanut Allergy Therapeutics Introduction

11.4.4 J & J Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.4.5 J & J Recent Development

11.5 Perrigo

11.5.1 Perrigo Company Detail

11.5.2 Perrigo Business Overview

11.5.3 Perrigo Peanut Allergy Therapeutics Introduction

11.5.4 Perrigo Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.5.5 Perrigo Recent Development

11.6 GSK

11.6.1 GSK Company Detail

11.6.2 GSK Business Overview

11.6.3 GSK Peanut Allergy Therapeutics Introduction

11.6.4 GSK Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.6.5 GSK Recent Development

11.7 Kaleo

11.7.1 Kaleo Company Detail

11.7.2 Kaleo Business Overview

11.7.3 Kaleo Peanut Allergy Therapeutics Introduction

11.7.4 Kaleo Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.7.5 Kaleo Recent Development

11.8 Amneal Pharma

11.8.1 Amneal Pharma Company Detail

11.8.2 Amneal Pharma Business Overview

11.8.3 Amneal Pharma Peanut Allergy Therapeutics Introduction

11.8.4 Amneal Pharma Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.8.5 Amneal Pharma Recent Development

11.9 ALK Abello

11.9.1 ALK Abello Company Detail

11.9.2 ALK Abello Business Overview

11.9.3 ALK Abello Peanut Allergy Therapeutics Introduction

11.9.4 ALK Abello Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.9.5 ALK Abello Recent Development

11.10 Aimmune Therapeutics

11.10.1 Aimmune Therapeutics Company Detail

11.10.2 Aimmune Therapeutics Business Overview

11.10.3 Aimmune Therapeutics Peanut Allergy Therapeutics Introduction

11.10.4 Aimmune Therapeutics Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.10.5 Aimmune Therapeutics Recent Development

11.11 HUAPONT Pharm

11.11.1 HUAPONT Pharm Company Detail

11.11.2 HUAPONT Pharm Business Overview

11.11.3 HUAPONT Pharm Peanut Allergy Therapeutics Introduction

11.11.4 HUAPONT Pharm Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.11.5 HUAPONT Pharm Recent Development

11.12 Allergy Therapeutics

11.12.1 Allergy Therapeutics Company Detail

11.12.2 Allergy Therapeutics Business Overview

11.12.3 Allergy Therapeutics Peanut Allergy Therapeutics Introduction

11.12.4 Allergy Therapeutics Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.12.5 Allergy Therapeutics Recent Development

11.13 ASIT Biotech

11.13.1 ASIT Biotech Company Detail

11.13.2 ASIT Biotech Business Overview

11.13.3 ASIT Biotech Peanut Allergy Therapeutics Introduction

11.13.4 ASIT Biotech Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.13.5 ASIT Biotech Recent Development

11.14 Sanofi

11.14.1 Sanofi Company Detail

11.14.2 Sanofi Business Overview

11.14.3 Sanofi Peanut Allergy Therapeutics Introduction

11.14.4 Sanofi Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.14.5 Sanofi Recent Development

11.15 DBV Technologies

11.15.1 DBV Technologies Company Detail

11.15.2 DBV Technologies Business Overview

11.15.3 DBV Technologies Peanut Allergy Therapeutics Introduction

11.15.4 DBV Technologies Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.15.5 DBV Technologies Recent Development

11.16 HAL Allergy

11.16.1 HAL Allergy Company Detail

11.16.2 HAL Allergy Business Overview

11.16.3 HAL Allergy Peanut Allergy Therapeutics Introduction

11.16.4 HAL Allergy Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.16.5 HAL Allergy Recent Development

11.17 Intrommune Therapeutics

11.17.1 Intrommune Therapeutics Company Detail

11.17.2 Intrommune Therapeutics Business Overview

11.17.3 Intrommune Therapeutics Peanut Allergy Therapeutics Introduction

11.17.4 Intrommune Therapeutics Revenue in Peanut Allergy Therapeutics Business (2017-2022)

11.17.5 Intrommune Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

Choose License Type

Checkout Inquiry Sample